Chemotherapy Induced Anemia - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chemotherapy Induced Anemia - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chemotherapy Induced Anemia - Pipeline Review, H1 2015', provides an overview of the Chemotherapy Induced Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Anemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Anemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chemotherapy Induced Anemia Overview 7
Therapeutics Development 8
Pipeline Products for Chemotherapy Induced Anemia - Overview 8
Pipeline Products for Chemotherapy Induced Anemia - Comparative Analysis 9
Chemotherapy Induced Anemia - Therapeutics under Development by Companies 10
Chemotherapy Induced Anemia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Chemotherapy Induced Anemia - Products under Development by Companies 14
Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development 15
3SBio Inc. 15
Aprogen, Inc. 16
Avesthagen Limited 17
Panacea Biotec Limited 18
Pieris AG 19
ProMetic Life Sciences Inc. 20
Sandoz International GmbH 21
Therapure Biopharma Inc. 22
Tolero Pharmaceuticals, Inc. 23
Chemotherapy Induced Anemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
darbepoetin alfa - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
darbepoetin alfa - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
darbepoetin alfa - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
epoetin alfa (recombinant) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NuPIAO - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PBI-1402 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
PBI-4494 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PRS-080 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TBI-304 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
TP-0413 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
TXA-302 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Chemotherapy Induced Anemia - Recent Pipeline Updates 47
Chemotherapy Induced Anemia - Dormant Projects 49
Chemotherapy Induced Anemia - Discontinued Products 50
Chemotherapy Induced Anemia - Product Development Milestones 51
Featured News & Press Releases 51
Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 51
Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world's first complex biosimilar 51
Jan 07, 2008: Sandoz and Gambro form strategic alliance 52
Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables
Number of Products under Development for Chemotherapy Induced Anemia, H1 2015 8
Number of Products under Development for Chemotherapy Induced Anemia - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Chemotherapy Induced Anemia - Pipeline by 3SBio Inc., H1 2015 15
Chemotherapy Induced Anemia - Pipeline by Aprogen, Inc., H1 2015 16
Chemotherapy Induced Anemia - Pipeline by Avesthagen Limited, H1 2015 17
Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Limited, H1 2015 18
Chemotherapy Induced Anemia - Pipeline by Pieris AG, H1 2015 19
Chemotherapy Induced Anemia - Pipeline by ProMetic Life Sciences Inc., H1 2015 20
Chemotherapy Induced Anemia - Pipeline by Sandoz International GmbH, H1 2015 21
Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc., H1 2015 22
Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Chemotherapy Induced Anemia Therapeutics - Recent Pipeline Updates, H1 2015 47
Chemotherapy Induced Anemia - Dormant Projects, H1 2015 49
Chemotherapy Induced Anemia - Discontinued Products, H1 2015 50